Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

KNTE

Kinnate Biopharma (KNTE)

Kinnate Biopharma Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:KNTE
DateTimeSourceHeadlineSymbolCompany
04/04/202400:00GlobeNewswire Inc.XOMA Corporation Announces Closing of Tender OfferNASDAQ:KNTEKinnate Biopharma Inc
20/03/202407:05GlobeNewswire Inc.XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.NASDAQ:KNTEKinnate Biopharma Inc
06/03/202409:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KNTEKinnate Biopharma Inc
06/03/202409:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KNTEKinnate Biopharma Inc
05/03/202409:27Edgar (US Regulatory)Form SC 14D9 - Solicitation, recommendation statementsNASDAQ:KNTEKinnate Biopharma Inc
02/03/202400:53Edgar (US Regulatory)Form SC14D9C - Written communication relating to third party tender offerNASDAQ:KNTEKinnate Biopharma Inc
02/03/202400:50Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KNTEKinnate Biopharma Inc
02/03/202400:35PR Newswire (US)Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre LaboratoriesNASDAQ:KNTEKinnate Biopharma Inc
02/03/202400:35PR Newswire (US)Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre LaboratoriesNASDAQ:KNTEKinnate Biopharma Inc
02/03/202400:35PR Newswire (Canada)Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre LaboratoriesNASDAQ:KNTEKinnate Biopharma Inc
02/03/202400:30GlobeNewswire Inc.Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre LaboratoriesNASDAQ:KNTEKinnate Biopharma Inc
21/02/202422:01Edgar (US Regulatory)Form SC14D9C - Written communication relating to third party tender offerNASDAQ:KNTEKinnate Biopharma Inc
17/02/202409:57PR Newswire (US)ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Kinnate Biopharma Inc.NASDAQ:KNTEKinnate Biopharma Inc
17/02/202402:46PR Newswire (US)Kuehn Law Encourages KNTE, FANG, HAYN, and VINE Investors to Contact Law FirmNASDAQ:KNTEKinnate Biopharma Inc
17/02/202401:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KNTEKinnate Biopharma Inc
17/02/202400:00GlobeNewswire Inc.XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value RightNASDAQ:KNTEKinnate Biopharma Inc
17/02/202400:00GlobeNewswire Inc.Kinnate Biopharma Inc. Enters into Agreement to be Acquired by XOMA Corporation for Between $2.3352 and $2.5879 Per Share in Cash, Plus One Contingent Value Right per ShareNASDAQ:KNTEKinnate Biopharma Inc
15/02/202401:21Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:KNTEKinnate Biopharma Inc
17/01/202408:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KNTEKinnate Biopharma Inc
06/12/202309:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KNTEKinnate Biopharma Inc
06/12/202309:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KNTEKinnate Biopharma Inc
16/11/202301:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KNTEKinnate Biopharma Inc
10/11/202308:21Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KNTEKinnate Biopharma Inc
10/11/202308:14Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KNTEKinnate Biopharma Inc
10/11/202308:05GlobeNewswire Inc.Kinnate Biopharma Inc. Reports Third Quarter 2023 Financial Results and Recent Corporate UpdatesNASDAQ:KNTEKinnate Biopharma Inc
19/09/202306:28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KNTEKinnate Biopharma Inc
19/09/202306:10GlobeNewswire Inc.Kinnate Biopharma Inc. Announces Pipeline Updates, Strategic Reprioritization and Workforce RestructuringNASDAQ:KNTEKinnate Biopharma Inc
07/09/202307:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KNTEKinnate Biopharma Inc
07/09/202307:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KNTEKinnate Biopharma Inc
09/08/202306:48Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KNTEKinnate Biopharma Inc
 Showing the most relevant articles for your search:NASDAQ:KNTE